Our publications at a glance.
Publications
Our scientific publications
Emrusolmin (anle138b) is an innovative oligomer modulator that has the potential to influence the course of neurodegenerative diseases such as multiple system atrophy. Detailed information on the mode of action and the promising study results can be found here.
SAA technology, also known as RT-QuIC, enables the highly sensitive and specific detection of misfolded proteins such as alpha-synuclein and prions in biological samples. This method offers promising approaches for the early diagnosis and monitoring of neurodegenerative diseases. Read more here.
Our research on PET tracers aims to visualize pathological protein deposits such as alpha-synuclein in order to better diagnose neurodegenerative diseases and monitor their progression. You can find out more about this in our publications.
Emrusolmin (anle138b)
NATURE COMMUNICATIONS
The clinical drug candidate anle138b binds in a cavity of lipidic α-synuclein fibrils.
THE LANCET – eBioMedicine
Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomized, double-blind, placebo-controlled phase 1a trial.
Acta Neuropathologica
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease.
Acta Neuropathologica
The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset.
Acta Neuropathologica
Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies.
ACS Chemical Neuroscience
Resolving the Atomistic Modes of Anle138b Inhibitory Action on Peptide Oligomer Formation.
EMBO Molecular Medicine
The diphenylpyrazole compound anle138b blocks Ab channels and rescues disease phenotypes in a mouse model for amyloid pathology.
Movement Disorders
Anle138b Modulates α-Synuclein Oligomerization and Prevents Motor Decline and Neurodegeneration in a Mouse Model of Multiple System Atrophy.
Acta Neuropathologica
Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model.
Alzheimer’s Research & Therapy
Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau.
Our aim is to develop novel therapeutics based on the molecular principles.
SAA / RT-QuIC
Acta Neuropathologica
A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease.
Acta Neuropathologica Communications
Establishing quantitative real-time quaking-induced conversion (qRT-QuIC) for highly sensitive detection and quantification of PrPSc in prion-infected tissues.
Journal of Neuropathology & Experimental Neurology
Quantitative Real-Time Quaking-Induced Conversion Allows Monitoring of Disease-Modifying Therapy in the Urine of Prion-Infected Mice.
FEBS Open Bio
Potential sources of interference with the highly sensitive detection and quantification of alpha-synuclein seeds by qRT-QuIC.
Faster and more precise diagnoses
with PD DETECT
SAA:
The future of protein diagnostics
PET tracer development
European Journal of Nuclear Medicine and Molecular Imaging
[MODAG-001-towards a PET tracer targeting α-synuclein aggregates.
ChemMedChem
¹¹C Radiolabeling of anle253b: a Putative PET Tracer for Parkinson’s Disease That Binds to α-Synuclein Fibrils in vitro and Crosses the Blood-Brain Barrier.